Search

Your search keyword '"Tammy Hayes"' showing total 2 results
Start Over Author "Tammy Hayes" Topic medicine
2 results on '"Tammy Hayes"'

1. Mpox infection of stromal cells and macrophages of macaque with endometriosis

Author

Joshua M. Hall, Claire E. Lyons, Jingyi Li, Gisela Martinez-Romero, Tammy Hayes, Anthony Cook, Dan H. Barouch, and Amanda J. Martinot

Subjects
Medicine, Science
Abstract

Abstract The mpox outbreak of 2022–2023 represented a new global health challenge and recognition of mpox as a sexually transmitted disease. The majority of cases were reported in men who have sex with men (MSM), but women are also susceptible, especially during pregnancy. We evaluated the reproductive tracts of a subset of macaques from a large rechallenge study of mpox infection with virus from the 2022 outbreak and identified intraabdominal mpox replication associated with endometriosis. Mpox virus (MPXV) was found not only in skin, but in the cervix, the uterus, and periovarian endometriotic lesions of the affected macaque. Mpox replication preferentially targeted vimentin-positive poorly differentiated endometriotic stromal tissue and infiltrating macrophages in the reproductive tract. Mpox tropism for stromal cells and macrophages has broad implications for mpox pathogenesis and associated clinical syndromes. In addition, women with endometriosis may be at heightened risk for adverse outcomes associated with mpox infection. The rhesus macaque provides rare insight into this disease and the potential complications of mpox infection in the context of genitourinary tract disease.

Published
2024
Full Text
View/download PDF

2. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques

Author

Lisa H. Tostanoski, David R. Martinez, Laurent Pessaint, Deandre Bueno-Wilkerson, Felix Nampanya, Jinyan Liu, Abishek Chandrashekar, Daniel Valentin, Frank Wegmann, Katherine McMahan, Anthony L. Cook, Mark G. Lewis, Hanne Leth Andersen, Noe B. Mercado, Victoria M. Giffin, Ralph S. Baric, Renita Brown, Huahua Wan, Sarah Gardner, Caroline Atyeo, Roland Zahn, Galit Alter, Daniel Sellers, Amanda J. Martinot, Zack Flinchbaugh, Tochi Anioke, Shivani A. Patel, Aiquan Chang, Jingyou Yu, Tammy Hayes, Dan H. Barouch, Hanneke Schuitemaker, Owen Sanborn, David L. Hope, Joseph P. Nkolola, Catherine Jacob-Dolan, Esther A. Bondzie, Katherine Bauer, and Elyse Teow

Subjects
Male, 0301 basic medicine, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), T-Lymphocytes, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Nose, Antibodies, Viral, Virus Replication, Article, Virus, 03 medical and health sciences, 0302 clinical medicine, Immune system, medicine, Animals, 030212 general & internal medicine, Vaccines, Immunity, Cellular, Multidisciplinary, Ad26COVS1, biology, medicine.diagnostic_test, SARS-CoV-2, COVID-19, Antibodies, Neutralizing, Macaca mulatta, Virology, Immunity, Humoral, 030104 developmental biology, Bronchoalveolar lavage, Viral replication, biology.protein, Female, Antibody, Bronchoalveolar Lavage Fluid, CD8
Abstract

The emergence of SARS-CoV-2 variants that partially evade neutralizing antibodies poses a threat to the efficacy of current COVID-19 vaccines1,2. The Ad26.COV2.S vaccine expresses a stabilized spike protein from the WA1/2020 strain of SARS-CoV-2, and has recently demonstrated protective efficacy against symptomatic COVID-19 in humans in several geographical regions—including in South Africa, where 95% of sequenced viruses in cases of COVID-19 were the B.1.351 variant3. Here we show that Ad26.COV2.S elicits humoral and cellular immune responses that cross-react with the B.1.351 variant and protects against B.1.351 challenge in rhesus macaques. Ad26.COV2.S induced lower binding and neutralizing antibodies against B.1.351 as compared to WA1/2020, but elicited comparable CD8 and CD4 T cell responses against the WA1/2020, B.1.351, B.1.1.7, P.1 and CAL.20C variants. B.1.351 infection of control rhesus macaques resulted in higher levels of virus replication in bronchoalveolar lavage and nasal swabs than did WA1/2020 infection. Ad26.COV2.S provided robust protection against both WA1/2020 and B.1.351, although we observed higher levels of virus in vaccinated macaques after B.1.351 challenge. These data demonstrate that Ad26.COV2.S provided robust protection against B.1.351 challenge in rhesus macaques. Our findings have important implications for vaccine control of SARS-CoV-2 variants of concern., SARS-CoV-2 challenge of rhesus macaques demonstrates that the Ad26.COV2.S vaccine induces robust protection against both the WA1/2020 isolate and the B.1.351 variant of concern.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results